<DOC>
	<DOCNO>NCT02987543</DOCNO>
	<brief_summary>The purpose study evaluate efficacy safety olaparib versus enzalutamide abiraterone acetate subject metastatic castration-resistant prostate cancer fail prior treatment new hormonal agent homologous recombination repair gene mutation .</brief_summary>
	<brief_title>Study Olaparib ( Lynparza™ ) Versus Enzalutamide Abiraterone Acetate Men With Metastatic Castration-Resistant Prostate Cancer ( PROfound Study )</brief_title>
	<detailed_description>This prospective , multicenter , randomize , open-label , phase 3 trial evaluate efficacy safety olaparib versus enzalutamide abiraterone subject metastatic castration-resistant prostate cancer ( mCRPC ) fail prior treatment new hormonal agent ( NHA ) qualify tumor mutation one 15 gene involve homologous recombination repair ( HRR ) pathway . Subjects divide two cohort base HRR gene mutation status . Approximately 340 subject randomize 2:1 ( olaparib : investigator choice enzalutamide abiraterone acetate ) trial .</detailed_description>
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>Olaparib</mesh_term>
	<mesh_term>Abiraterone Acetate</mesh_term>
	<criteria>Inclusion criterion 1 . Histologically confirm diagnosis prostate cancer . 2 . Documented evidence metastatic castration resistant prostate cancer ( mCRPC ) . 3 . Subjects must progress prior new hormonal agent ( e.g . abiraterone acetate and/or enzalutamide ) treatment mCRPC . 4 . Ongoing therapy LHRH analog bilateral orchiectomy . 5 . Radiographic progression study entry androgen deprivation therapy ( bilateral orchiectomy ) . 6 . Qualifying HRR mutation tumor tissue . Exclusion criteria 1 . Any previous treatment PARP inhibitor , include olaparib . 2 . Subjects previous treatment DNAdamaging cytotoxic chemotherapy ( prior taxane chemotherapy allow ) . 3 . Other malignancy ( include MDS MGUS ) within last 5 year except : adequately treat nonmelanoma skin cancer solid tumor curatively treat evidence disease ≥5 year . 4 . Subjects know brain metastasis .</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2017</verification_date>
	<keyword>metastatic castration-resistant prostate cancer ( mCRPC )</keyword>
	<keyword>homologous recombination repair ( HRR )</keyword>
</DOC>